Skip to Content

News & Insights

News & Insights

News & Insights

Perspective Shares CSO Placement Successes

Jun 21

Written By Sarah Foster

Sarah Foster

Perspective shares R & D Placement Successes

89bio, Inc. (San Francisco, CA), Vice President, Clinical Development – Wenyan Wang, Ph.D. (former Vice President and Global Leader, Centessa Pharmaceuticals)

Aadi Bioscience (Morristown, NJ), Chief Executive Officer – David Lennon, Ph.D. (former Chief Executive Officer, Satellite Bio)

Acrivon Therapeutics (Watertown, MA), Board Director – Charles Baum, M.D., Ph.D. (President, Founder, Head of Research and Development, Mirati Therapeutics)

Agios Pharmaceuticals (Cambridge, MA), Vice President, Investor Relations and Corporate Communications – Chris Taylor (former Vice President, Investor Relations and Corporate Communications, Codiak BioSciences)

Akamis Bio (Cambridge, MA), Chief Medical Officer - Oliver Rosen, M.D. (former President and Chief Medical Officer, DynamiCure Biotechnology)

ALX Oncology (San Francisco, CA), Chief Executive Officer – Jason Lettmann (former General Partner, Lightstone Ventures)

C4 Therapeutics (Watertown, MA), Board Director – Owen Hughes (former Chief Executive Officer, Cullinan Oncology)

Chinook Therapeutics (Seattle, WA), Chief Commercial Officer – Andrew Oxtoby (former Chief Executive Officer, Aimmune Therapeutics)

Covant Therapeutics (Boston, MA), Chief Executive Officer – Vincent Hennemand (former Chief Operating Officer, Intergalactic Therapeutics)

Editas Medicine (Cambridge, MA), Chief Financial Officer – Erick Lucera (former Chief Financial Officer, AVEO Pharmaceuticals)

Inozyme Pharma (Cambridge, MA), Chief Operating Officer – Matthew Winton, Ph.D. (former Senior Vice President, Head of US MS Franchise, Biogen)

Judo Bio (Cambridge, MA), Chief Scientific Officer – Alfica Sehgal, Ph.D. (former Senior Vice President, Head of Discovery and Translation, CAMP4 Therapeutics)

Korro Bio (Cambridge, MA), Audit Chair – Tim Pearson (Chief Executive Officer, Carrick Therapeutics)

Kymera Therapeutics, Inc. (Watertown, MA), Chief Operating Officer – Jeremy Chadwick, Ph.D. (former Senior Vice President and Head of Global Development Office, R&D, Takeda Pharmaceuticals)

Liberate Bio (Brighton, MA), Chief Executive Officer – Shawn Davis, Ph.D. (former Executive Director, Drug Delivery, AstraZeneca)

Mitochondria eMotion, Inc. (Cambridge, MA), Vice President, Head of Biology – Matthew Jarpe, Ph.D. (former Vice President of Target Biology, Korro Bio, Inc.)

Monte Rosa Therapeutics (Boston, MA), Board Director – Jan Skvarka, Ph.D. (former President and Chief Executive Officer, Trillium Therapeutics)

Mural Oncology (Waltham, MA), Chief Executive Officer – Caroline Loew, Ph.D. (former President and Chief Executive Officer, Glympse Bio)

Mural Oncology (Waltham, MA), Chief Financial Officer – Adam Cutler (former Chief Financial Officer, Q32 Bio)

Mural Oncology (Waltham, MA), Chief Medical Officer – Vicki Goodman, M.D. (former Chief Medical Officer, Exelixis)

Mural Oncology (Waltham, MA), Board Director – Susan Altschuller, Ph.D. (Chief Financial Officer, Cerevel Therapeutics)

Mural Oncology (Waltham, MA), Board Director – Francis Cuss, MB, BChir. (former Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb)

Mural Oncology (Waltham, MA), Board Director – Benjamin Hickey (Chief Commercial Officer, Mirati Therapeutics)

Mural Oncology (Waltham, MA), Board Director – Scott Jackson (former Chief Executive Officer, Celator Pharmaceuticals)

Nested Therapeutics (Cambridge, MA), Board Director – Anna Berkenblit, M.D. (former Senior Vice President and Chief Medical Officer, ImmunoGen, Inc.)

Nested Therapeutics (Cambridge, MA), Chief Business Officer – Tanja Weber (former Chief Business Officer, Epizyme)

Prime Medicine, Inc (Cambridge, MA), Chief Financial Officer - Allan Reine, M.D. (former Chief Financial Officer, Foghorn Therapeutics)

Provention Bio, Inc. (Red Bank, NJ), Board Director – Rita Jain, M.D. (former Executive Vice President and Chief Medical Officer, ChemoCentryx)

Rectify Pharmaceuticals (Cambridge, MA), Chief Operating Officer – Sachiyo Minegishi (former Chief Financial Officer, Akouos)

Remix Therapeutics (Cambridge, MA), Chief Financial Officer – Robert Gagnon (former Chief Financial Officer, Verastem Oncology)

Rome Therapeutics (Cambridge, MA), Chief Financial Officer and Chief Business Officer – Kyle Kuvalanka (former Chief Financial Officer and Chief Operating Officer, Goldfinch Bio)

Scribe Therapeutics (Alameda, CA), Chief Scientific Officer – Aarif Khakoo, M.D. (former Chief Medical Officer and Head of Drug Development, Calico Life Sciences)

Solid Biosciences (Cambridge, MA), Chief Medical Officer – Gabriel Brooks, M.D. (former Executive Director, Pfizer)

Spero Therapeutics (Cambridge, MA), Chief Executive Officer – Sath Shukla (former Chief Financial Officer, Spero Therapeutics)

Tallac Therapeutics (Burlingame, CA), Chief Medical Officer – Kevin Heller, M.D. (former Executive Vice President, Research and Development, Jasper Therapeutics)

Triana Biomedicines (Lexington, MA), Chief Business Officer – Reza Mazhari, Ph.D. (former Head of Search and Evaluation, North America, Business Development and Licensing, Novartis)

Perspective Group LLC | One Broadway Cambridge MA 02142 | Privacy Policy | © 2022 Perspective